Understanding the burden of idiopathic generalized epilepsy in the United States, Europe, and Brazil: An analysis from the National Health and Wellness Survey  by Gupta, Shaloo et al.
Epilepsy & Behavior 55 (2016) 146–156
Contents lists available at ScienceDirect
Epilepsy & Behavior
j ourna l homepage: www.e lsev ie r .com/ locate /yebehUnderstanding the burden of idiopathic generalized epilepsy in the
United States, Europe, and Brazil: An analysis from the National Health
and Wellness SurveyShaloo Gupta a,⁎, Patrick Kwan b, Edward Faught c, Wan Tsong d, Anna Forsythe d, Phillipe Ryvlin e
a Kantar Health, 1 Independence Way, Suite 220, Princeton, NJ 08540, USA
b The University of Melbourne and Royal Melbourne Hospital, Parkville, VIC 3050, Australia
c Emory University School of Medicine, Emory Epilepsy Program, 12 Executive Park Drive NE, Atlanta, GA 30329, USA
d Eisai Inc., Global Value & Access, 155 Tice Blvd., Woodcliff Lake, NJ 07677, USA
e Centre Hospitalier Universitaire Vaudois, Département des Neurosciences Cliniques, BH/10/137 Rue du Bugnon 46, CH-1011 Lausanne, Switzerland⁎ Corresponding author at: Health Outcomes Practice,
Way, Suite 220, Princeton, NJ 08540, USA. Tel.: +1 609 72
E-mail addresses: shaloo.gupta@kantarhealth.com (S.
patrick.kwan@unimelb.edu.au (P. Kwan), rfaught@emory
wan_tsong@eisai.com (W. Tsong), anna_forsythe@eisai.co
philippe.ryvlin@gmail.com (P. Ryvlin).
http://dx.doi.org/10.1016/j.yebeh.2015.12.018
1525-5050/© 2015 The Authors. Published by Elsevier Inca b s t r a c ta r t i c l e i n f oArticle history:
Received 13 November 2015
Revised 1 December 2015
Accepted 10 December 2015
Available online 14 January 2016The aimof this studywas to understand the current burden of primary generalized tonic–clonic seizures (PGTCS) as-
sociatedwith idiopathic generalized epilepsy (IGE) as a function of seizure frequency.We analyzed data for (IGE) as a
proxy measure of PGTCS. Little is known about the quality of life (QoL), health utility, productivity, healthcare re-
source utilization (HRU), and cost burden of PGTCS or IGE. Patients were identiﬁed from the US (2011, 2012, &
2013), 5EU (2011 & 2013), and Brazil (2011 & 2012) National Health andWellness Survey, a nationally representa-
tive, internet-based survey of adults (18+years). Patients that self-reported a diagnosis of IGEwere categorized into
seizure frequencies of: ≥1 seizure per week, 1–3 seizures per month, 1–4 seizures per year, or b1 seizure per year.
QoLwasmeasured using the SF-36v2Mental (MCS) and Physical Component Summary (PCS) scores, health utilities
with the SF-6D, productivitywith theWork Productivity and Activity Impairment (WPAI) questionnaire, andHRU as
reported in the past six months. Unit costs were estimated from the literature andmultiplied against HRU values to
calculate direct costs andWPAI values to calculate indirect costs. Generalized linear regressionwas utilized to exam-
ine the relationship between seizure frequency and each measure of burden with adjustment for covariates. Out of
the general population surveyed, IGE was self-reported in 782 of 176,093 (US), 172 of 30,000 (UK), 106 of 30,001
(Germany), 87 of 30,000 (France), 31 of 12,011 (Spain), 22 of 17,500 (Italy), and 34 of 24,000 (Brazil). Persistent sei-
zures (≥1 per year) were reported in over 40% of patients with IGE (10–15%with ≥1 seizure per week, 10–15%with
1–3 seizures permonth, 20–25%with 1–4 seizures per year). Over 75%were treatedwith antiepileptic drugs (AEDs).
Compared with those having b1 seizure per year (reference group), patients in the two most frequent seizure cate-
gories reportedworseMCS andPCS scores. Patients in the threehighest seizure frequency groups consistently report-
edworse health utility scores, and greater presenteeism (attendingworkwhile not physically ormentally capable of
working), overall work impairment, activity impairment, HRU, indirect costs, and direct costs than the reference
group. Despite the availability of AEDs during the year surveyed, a substantial number of patients experienced per-
sistent seizures. Increasing seizure frequency was clearly associated with worse outcomes. The burden of PGTCS
and IGE may be proportionally reduced by newer AEDs which may increase the proportion of seizure-free patients
or shift more patients into lower seizure frequency categories.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Very little research is published on primary generalized tonic–
clonic seizures (PGTCS) associated with idiopathic generalized epilepsyKantar Health, 1 Independence
0 5484.
Gupta),
.edu (E. Faught),
m (A. Forsythe),
. This is an open access article under(IGE) or genetic generalized epilepsy (GGE) [the current preferred ter-
minology of the International League Against Epilepsy]. Although the
majority of patients that would have been previously classiﬁed as IGE
would now be classiﬁed as GGE, the term IGE will be used when it re-
ﬂects that actual terminology used in original research. Seventy-four
percent of children and adults with IGE have PGTCS as one of their sei-
zure types [1]. The vast majority of studies include all patients with ep-
ilepsy where IGE comprises a mere 24% of the total population [2]. Of
PGTCS and IGE/GGE publications, we are aware of only 1 burden study
[3] that evaluates quality of life (QoL) in 19 patients with IGE. We arethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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healthcare resource utilization, or cost data for patients with PGTCS or
IGE/GGE living in the US, 5EU (France, Germany, Italy, Spain, and
United Kingdom), or Brazil in the public domain. Furthermore, we are
aware of no other studies which evaluate these burden parameters as
a function of actual seizure frequency. These data are vital to producing
economic evaluations in PGTCS and IGE/GGE. Of published economic
evaluations, we did not ﬁnd any speciﬁcally for PGTCS or IGE/GGE.
This study of adults with epilepsy has substantial value in under-
standing the burden of illness of PGTCS and IGE/GGE overall and by
seizure frequency. The results published here will be informative for
both healthcare decision-makers and builders of economic evaluations
in adult patients with PGTCS and IGE/GGE. Therefore, the objective of
this study was to understand the association of IGE/GGE on QoL, health
utilities, productivity loss, healthcare resource utilization, and indirect
and direct costs as a function of seizure frequency among adults with
IGE/GGE from the US, 5EU, and Brazil.
2. Methods
2.1. Sample and procedure
The current study includes data from the 2011, 2012, and 2013 (US),
2011 and 2012 (Brazil), and 2011 and 2013 (5EU: France, Germany,
Italy, Spain, and the UK; the survey was not ﬁelded in 2012) National
Health and Wellness Survey (NHWS; www.kantarhealth.com). The
NHWS is a self-administered, internet-based questionnaire from a sample
of adults (aged 18 years or older) in the seven countries of interest: US,
France, Germany, Italy, Spain, the UK, and Brazil. Potential NHWS partici-
pants were identiﬁed using Lightspeed Research, an opt-in online survey
panel, and its afﬁliates. The NHWS is intended to represent the entire
adult populationof a given countrybyemploying a stratiﬁed randomsam-
pling framework. The demographic distributions of each countrywere ob-
tained from the US Census Bureau (for the US) or the International
Database of the US Census Bureau (in the case of all other countries). Po-
tential respondentswere selected in such away as tomirror these charac-
teristics. Speciﬁcally, the age and gender distributionswerematched in all
countries. Additional matching for race/ethnicity distributions were per-
formed for the US. The NHWS study protocol was approved by Essex IRB
(Lebanon, NJ). Informed consent was obtained from all participants, and
participants' privacy rights were observed at all times. Previous research
has been published using data for the US, 5EU, and Brazil NHWS [4–6].
In all countries, the primarymethod of data collectionwas through the
internet. For countries with suboptimal internet penetration (France,
Germany, Italy, Spain, and Brazil), supplemental recruiting through com-
puter assistedweb interviews (CAWI)was performed, particularly among
older age groups. In the cases of CAWI recruiting, potential respondents
were recruited by telephone andhad the choice to complete the interview
on the phone while the interviewer entered the responses online or to
complete the survey on their own andwere e-mailed a link to the survey.
This study included combined data from the 2011, 2012, and 2013
NHWS. The current study pooled together multiple years of data to in-
crease the sample size of respondents with IGE (the terminology used
in the original survey). It is possible for a respondent to complete
more than one survey across multiple years. In these instances, only
the most recent data for a given respondent were kept.
Respondents were identiﬁed from adults who self-reported a diag-
nosis of epilepsy with IGE (“What type of epilepsy have you been diag-
nosed with?” and selected “Idiopathic Generalized Epilepsy [Myoclonic
seizures, Absence seizures, or Grand Mal seizures]”) on the NHWS.
2.2. Measures
2.2.1. Seizure frequency
The NHWS asked respondents “How often do you experience a
seizure?” with the following options: more than once a week, oncea week, two or three times a month, once a month, every three
months, every six months, once a year, or less than once a year. These
responses were then used to create the categories representing seizure
frequency for adult patients with IGE (once aweek ormore, 1–3 times a
month, 1–4 times a year, or less than once a year). The assessment was
not repeated by seizure type and represents the total of all IGE seizure
types.
2.2.2. Demographics
Survey respondents reported their age, gender, race/ethnicity (only
US), marital status, education, annual household income, employment
status, and insurance status (only US).
2.2.3. Health characteristics
Body mass index (BMI) was calculated from self-reported height
and weight. Alcohol consumption, smoking status, and exercise behav-
iors were also assessed. Self-reported comorbidity data were used to
calculate a comorbidity burden score using the Charlson Comorbidity
Index (CCI) [7]. The greater the total index score, the greater the comor-
bidity burden on the patient.
2.2.4. Epilepsy-speciﬁc characteristics
Survey respondents provided information on the number of years
diagnosed with epilepsy and the current prescription medications
used to treat epilepsy.
2.2.5. QoL
QoL was assessed using the Physical (PCS) and Mental Component
Summary (MCS) scores from the Short Form (SF)-12v2 (2011 NHWS)
and SF-36v2 (2012 and 2013 NHWS), as well as the health utility mea-
sure (SF-6D). The PCS andMCS scores are normed to the US population
(M=50, SD= 10), with higher scores indicating greater QoL [8,9]. The
health utility score is a preference-based single index measure for
health using general population values. A difference greater than 3 in
PCS or MCS was regarded as a minimally important difference (MID)
[10], and a difference greater than 0.041 on health utilities was identi-
ﬁed as a MID [11].
2.2.6. Work and activity impairment
The Work Productivity and Activity Impairment Questionnaire
(General Health version;WPAIGH) [12] consists of six itemsmeasuring
absenteeism, presenteeism (attending work while not physically or
mentally capable of working), overall work productivity loss, and activ-
ity impairment. Only employed respondents provided data for the
work-related items, but all respondents provided data for activity
impairment. Scores can range from 0 to 100%, with higher scores
representing greater impairment.
2.2.7. Healthcare utilization
Resource use was deﬁned by the number of traditional healthcare
provider visits (e.g., general practitioner, internist, neurologist) in the
past six months, the number of emergency room (ER) visits (“How
many times have you been to the ER for your own medical condition
in the past six months?”), and the number of times hospitalized
(“How many times have you been hospitalized for your own medical
condition in the past six months?”).
2.2.8. Direct costs
Total direct costs consisted of three components: cost of traditional
provider visits, cost of ER visits, and hospitalization costs. For each re-
spondent and visit type, the number of visits (in the past six months)
was multiplied by two to project to the annual number of visits, and
then multiplied by its average visit cost.
In the US, visit costs were calculated for an average provider visit, ER
visit, and hospitalization using the 2011Medical Expenditure Panel Sur-
vey data (http://www.ahrq.gov/research/data/meps/). In the 5EU, visit
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to 2013 values using the Eurostat health-related Harmonized Consumer
Prices Index. Because 5EU visit costs for a hospitalization were reported
per diem in the literature, the per diem valuewasmultiplied by three as
this was the median length of stay (LOS) in the latest NHWS survey
(2007) that assessed LOS.
2.2.9. Indirect costs
Total indirect costs were estimated for each respondent using the
human capital method. Speciﬁcally, wages were multiplied by the per-
centage of work productivity impairment and then annualized. The
WPAI-GH [12] was used to calculate productivity loss.
In the US, average gender-speciﬁc and age-speciﬁc (i.e., 18–24, 25–
34, 35–44, 45–54, 55–64, or 65+ years) wages were obtained from
the US Bureau of Labor Statistics (2012). In the 5EU, median annual in-
come (18 years or older) was obtained for each country from Eurostat
2012 annual net income ﬁgures [14]. Hourly wages were estimated by
dividing annual income by the typical number of weeks worked per
year and hours worked per week. Data on weeks and hours worked in
2012 were obtained from the European Foundation for the Improve-
ment of Living and Working Conditions [15].
2.3. Statistical analyses
2.3.1. Bivariate analyses to identify covariates for multivariable models
Individually for each region (US, 5EU, Brazil + 5EU), the relation-
ships between seizure frequency categories (reference group = less
than 1 seizure per year) and demographics (as listed earlier), health
characteristics (as listed earlier), and epilepsy-speciﬁc characteris-
tics (as listed earlier) were evaluated in bivariate analyses to identify
covariates for multivariable regression models. Chi-square tests
were used for categorical variables and ANOVAs for continuous
variables.
2.3.2. Multivariable models and pairwise comparisons
Scientiﬁcally relevant and data-informed variables were included
as covariates in multivariable regressionmodels predicting QoL, pro-
ductivity loss, healthcare resource utilization, and indirect and direct
costs, as a function of seizure frequency. These models controlled for
age, gender, race/ethnicity (only US), education, employment status
(not included in WPAI and indirect cost metrics), marital status, in-
surance status (only US and not included in WPAI and indirect cost
metrics), length of time diagnosed with epilepsy, and the CCI. Ad-
justed means from these models were reported for each seizure fre-
quency group using a maximum likelihood algorithm. Pairwise
multiple comparisons were made between higher seizure frequency
groups and the reference group (less than 1 seizure per year). There
was no adjustment for multiple comparisons. For all analyses, a
p b 0.05, two-tailed, was considered statistically signiﬁcant. All anal-
yses were conducted in SAS version 9.3 (SAS Institute, Cary, NC,
USA).
2.3.3. Special considerations for the Brazilian dataset
Due to the small sample size of Brazilian patient numbers (n= 34),
the total Brazil and 5EU IGE samples were compared on demographics,
health characteristics, and epilepsy characteristics to evaluate whether
it would be reasonable to combine the two datasets for the purpose of
estimating Brazilian outcomes. Because minimal differences were iden-
tiﬁed, the above multivariable analyses were conducted for Brazil using
a combined Brazil + 5EU dataset. No costing was performed on this
combined dataset.
3. Results
Out of the total NHWS population, 782 of 176,093 [0.44%] (US), 172
of 30,000 [0.57%] (UK), 106 of 30,001 [0.35%] (Germany), 87 of 30,000[0.29%] (France), 31 of 12,011 [0.26%] (Spain), 22 of 17,500 [0.13%]
(Italy), and 34 of 24,000 [0.14%] (Brazil) self-reported a diagnosis of
IGE. These results suggest a self-reported prevalence of 0.4% for IGE
among the entire study cohort.
Patient characteristics (Table 1) appeared to be qualitatively
different between the US and other datasets (5EU, Brazil + 5EU)
on certain estimates. Employment appeared lower and long-term
disability higher in the US. There appeared to be more obese patients
in the US, but fewer alcohol consumers and more nonsmokers. The
overall CCI was higher in the US. There were fewer patients with 0–
5 years of epilepsy and more with 31+ years of epilepsy in the US.
There were fewer monotherapy patients and more taking 2 antiepi-
leptic drugs (AEDs) in the US than other regions. The proportion of
patients taking any AEDs was similar between regions (75% US, 77%
5EU, 76% Brazil + 5EU) (Table 1). The proportion of patients with
persistent seizures (N1 per year) among AED users was slightly
higher in the US (51%) than the 5EU (45%) and Brazil + 5EU (45%)
[data not reported in tables]. Individual AED use varied somewhat
between regions (Table 1).
Table 2 demonstrates the similarities between the 5EU and
Brazil datasets on patient characteristics and outcomes. There were
small but statistically signiﬁcant differences on age, BMI, alcohol
consumption, duration of epilepsy, absenteeism, and overall work
impairment.
3.1. Bivariate results to determine covariates for multivariable outcomes
analyses of the relationship between seizure frequency and outcomes
Analyses were performed separately by region (US, 5EU, Brazil +
5EU). In the US analyses, seizure frequencywas statistically signiﬁcantly
associated with age, race/ethnicity, education, household income, em-
ployment status, long-termdisability, BMI, smoking status, CCI, epilepsy
duration, and total number of AEDs (Table 3). In the 5EU analyses,
seizure frequencywas associatedwith these same variableswith the ex-
ception of: variables that were not assessed in the 5EU (race/ethnicity),
variables not signiﬁcant for the 5EU (education, long-term disability,
BMI, and epilepsy duration), and variables signiﬁcant for the 5EU
(retirement) (Table 3). In the Brazil + 5EU dataset analyses, seizure fre-
quency was associated with the same factors as the 5EU dataset with
the exception of CCI which was marginally not signiﬁcant for the com-
bined dataset (Table 3).
3.2. Unadjusted and adjusted multivariable analyses of the relationship
between seizure frequency and outcomes
3.2.1. Unadjusted outcomes results
Unadjusted analyses examining the relationship between seizure
frequency and outcomes demonstrated statistically signiﬁcant associa-
tions between seizure frequency and all outcomes in all datasets with
the exception of absenteeism in the Brazil+ 5EU dataset. The directions
of the associations were as expected. Decreasing seizure frequency was
associatedwith improvedQoL scores (MCS, PCS, utilities), lesswork and
activity impairment (absenteeism, presenteeism, overall work impair-
ment, activity impairment), and lower healthcare resource use (provid-
er visits, ER visits, hospitalizations) (Table 4).
3.2.2. Adjusted multivariable outcomes results
3.2.2.1. US IGE. After adjustments for covariates identiﬁed through the
bivariate analysis, pairwise comparisons between the lowest seizure
frequency group (b1 seizure per year) and all other seizure frequency
groups indicated that patients reporting less than one seizure per year
had higher MCS and PCS QoL scores than the ≥1 seizures a week and
1–3 seizures per month groups (all p b 0.001). Differences in MCS and
PCS (N3) scores exceeded MIDs for these signiﬁcant comparisons. Pa-
tients that reported having less than one seizure per year had better
Table 1
Patient characteristics.
US values 5EU values Brazil + 5EU values
(N = 782) (N = 418) (N = 452)
Age (years) —mean ± SD 45.27 ± 14.46 43.64 ± 13.75 43.00 ± 13.70
Female (%) 388 (49.62%) 204 (48.80%) 225 (49.78%)
Race/ethnicity
Non-Hispanic white (%) 592 (75.70%) N/A N/A
Non-Hispanic black (%) 84 (10.74%) N/A N/A
Hispanic (%) 60 (7.67%) N/A N/A
Other ethnicity (%) 46 (5.88%) N/A N/A
Married/living with partner (%) 400 (51.15%) 244 (58.37%) 263 (58.19%)
College educated (%) 236 (30.18%) 147 (35.17%) 158 (34.96%)
Annual household income
b$25K, b€20K/b£20K, bR$ 1000 (%) 268 (34.27%) 153 (36.60%) 160 (35.40%)
$25K–b$50K, €20–b50K/£20–b40K, R$ 1001–R$ 6500 (%) 220 (28.13%) 165 (39.47%) 184 (40.71%)
$50K–b$75K, €50K+/£40K+, R$ 6501+ (%) 134 (17.14%) 60 (14.35%) 68 (15.04%)
$75K+ (%) 123 (15.73%) N/A N/A
Decline to answer (%) 37 (4.73%) 40 (9.57%) 40 (8.85%)
Employed (%) 351 (44.88%) 239 (57.18%) 257 (56.86%)
Retired (%) 101 (12.92%) 57 (13.64%) 58 (12.83%)
Long-term disability (%) 117 (14.96%) 39 (9.33%) 39 (8.63%)
Insured (%) 633 (80.95%) N/A N/A
Body mass index
Underweight (%) 27 (3.45%) 11 (2.63%) 15 (3.32%)
Normal weight (%) 217 (27.75%) 178 (42.58%) 189 (41.81%)
Overweight (%) 251 (32.10%) 122 (29.19%) 133 (29.42%)
Obese (%) 274 (35.04%) 91 (21.77%) 99 (21.90%)
Decline to provide weight (%) 13 (1.66%) 16 (3.83%) 16 (3.54%)
Consume alcohol (%) 423 (54.09%) 289 (69.14%) 303 (67.04%)
Smoking behavior
Nonsmoker (%) 355 (45.40%) 162 (38.76%) 181 (40.04%)
Former smoker (%) 230 (29.41%) 136 (32.54%) 143 (31.64%)
Current smoker (%) 197 (25.19%) 120 (28.71%) 128 (28.32%)
Exercise (%) 468 (59.85%) 235 (56.22%) 253 (55.97%)
Charlson comorbidity index —mean ± SD 0.79 ± 1.91 0.63 ± 2.38 0.67 ± 2.68
Length of time diagnosed with epilepsy
0 to 5 years (%) 74 (9.46%) 65 (15.55%) 72 (15.93%)
6 to 10 years (%) 85 (10.87%) 57 (13.64%) 58 (12.83%)
11 to 15 years (%) 105 (13.43%) 62 (14.83%) 65 (14.38%)
16 to 19 years (%) 62 (7.93%) 34 (8.13%) 35 (7.74%)
20 to 30 years (%) 143 (18.29%) 76 (18.18%) 89 (19.69%)
31 years or greater (%) 313 (40.03%) 124 (29.67%) 133 (29.42%)
Total number of epilepsy prescriptions
None (%) 195 (24.94%) 97 (23.21%) 109 (24.12%)
One medication (%) 380 (48.59%) 237 (56.70%) 252 (55.75%)
Two medications (%) 155 (19.82%) 59 (14.11%) 62 (13.72%)
Three or more medications (%) 52 (6.65%) 25 (5.98%) 29 (6.42%)
Antiepileptic medications (among AED-treated)
Acetazolamide NR 0.62% 0.58%
Carbamazepine 16.70% 21.18% 22.16%
Clobazam NR 0.62% 0.58%
Clonazepam NR 4.36% 6.12%
Diazepam NR 1.56% 1.46%
Eslicarbazepine NR 0.31% 0.29%
Ethosuximide NR 1.25% 1.17%
Gamibetal NR NR 0.29%
Gabapentin 5.96% 2.18% 2.33%
Lacosamide 3.75% 0.93% 0.87%
Lamotrigine 18.40% 24.61% 23.91%
Lorazepam NR 0.62% 0.58%
Levetiracetam 26.41% 17.76% 16.62%
Oxcarbazepine 3.58% 2.49% 2.33%
Perampanel 0.17% NR NR
Phenobarbital NR 5.92% 5.54%
Phenytoin 22.15% 7.48% 7.00%
Pregabalin 1.19% 2.18% 2.04%
Primidone NR 0.62% 0.58%
Ruﬁnamide 0.85% NR NR
Tiagabine 0.68% NR NR
Topiramate 11.07% 4.98% 4.66%
Valproate 16.35% 20.56% 20.70%
Zonisamide 3.75% 0.93% 0.87%
N/A = not applicable as these data were not collected in these countries, NR = not reported.
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Table 2
Evaluation of whether 5EU and Brazilian data can be combined.
Total 5EU IGE Brazil IGE p-Value
(N = 452) (N = 418) (N = 34)
Age (years) —mean ± SD 43.00 ± 13.70 43.64 ± 13.75 35.18 ± 10.33 b .001
Female (%) 225 (49.78%) 204 (48.80%) 21 (61.76%) 0.146
Married/living with partner (%) 263 (58.19%) 244 (58.37%) 19 (55.88%) 0.777
College educated (%) 158 (34.96%) 147 (35.17%) 11 (32.35%) 0.741
Employed (%) 257 (56.86%) 239 (57.18%) 18 (52.94%) 0.632
Retired (%) 58 (12.83%) 57 (13.64%) 1 (2.94%) 0.073
Long-term disability (%) 39 (8.63%) 39 (9.33%) 0 (0.00%) 0.062
Body mass index 0.038
Underweight (%) 15 (3.32%) 11 (2.63%) 4 (11.76%)
Normal weight (%) 189 (41.81%) 178 (42.58%) 11 (32.35%)
Overweight (%) 133 (29.42%) 122 (29.19%) 11 (32.35%)
Obese (%) 99 (21.90%) 91 (21.77%) 8 (23.53%)
Decline to provide weight (%) 16 (3.54%) 16 (3.83%) 0 (0.00%)
Drink alcohol (%) 303 (67.04%) 289 (69.14%) 14 (41.18%) b .001
Smoking behavior 0.134
Nonsmoker (%) 181 (40.04%) 162 (38.76%) 19 (55.88%)
Former smoker (%) 143 (31.64%) 136 (32.54%) 7 (20.59%)
Current smoker (%) 128 (28.32%) 120 (28.71%) 8 (23.53%)
Exercise (%) 253 (55.97%) 235 (56.22%) 18 (52.94%) 0.711
Charlson comorbidity index —mean ± SD 0.67 ± 2.68 0.63 ± 2.38 1.18 ± 5.14 0.257
Length of time diagnosed with epilepsy 0.039
0 to 5 years (%) 72 (15.93%) 65 (15.55%) 7 (20.59%)
6 to 10 years (%) 58 (12.83%) 57 (13.64%) 1 (2.94%)
11 to 15 years (%) 65 (14.38%) 62 (14.83%) 3 (8.82%)
16 to 19 years (%) 35 (7.74%) 34 (8.13%) 1 (2.94%)
20 to 30 years (%) 89 (19.69%) 76 (18.18%) 13 (38.24%)
31 years or greater (%) 133 (29.42%) 124 (29.67%) 9 (26.47%)
Using a prescription medication of epilepsy (%) 343 (75.88%) 321 (76.79%) 22 (64.71%) 0.113
MCS —mean ± SD 43.13 ± 12.09 43.21 ± 11.75 42.19 ± 15.89 0.637
PCS —mean ± SD 46.41 ± 10.48 46.20 ± 10.55 49.05 ± 9.40 0.128
Health utility —mean ± SD 0.67 ± 0.14 0.67 ± 0.14 0.68 ± 0.17 0.786
Absenteeisma,b (%) —mean ± SD 10.26 ± 23.44 9.30 ± 22.13 22.61 ± 34.94 0.020
Presenteeisma,b (%) —mean ± SD 24.42 ± 28.88 23.71 ± 28.49 34.38 ± 33.26 0.154
Overall work impairmenta,b (%) —mean ± SD 29.97 ± 33.20 28.72 ± 32.56 45.94 ± 38.06 0.034
Activity impairmentb (%) —mean ± SD 36.53 ± 32.26 36.51 ± 31.97 36.76 ± 36.07 0.964
Healthcare provider visits in past 6 months —mean ± SD 7.17 ± 9.57 7.15 ± 9.56 7.38 ± 9.87 0.891
ER visits in the past 6 months —mean ± SD 0.53 ± 1.39 0.51 ± 1.39 0.74 ± 1.48 0.374
Hospitalizations in the past 6 months —mean ± SD 0.37 ± 1.12 0.37 ± 1.14 0.38 ± 0.89 0.954
Note:Overall p-values are provided indicating that at least one group is different fromanother. Lower scores onMental Component Summary (MCS), Physical Component Summary (PCS),
and health utilities indicate a decrease in quality of life. Absenteeism, presenteeism, overall work impairment, and activity impairment scores represent impairment percentages, with
higher scores indicating greater impairment. ER = emergency room, IGE = idiopathic generalized epilepsy, SD = standard deviation.
a Includes only employed respondents.
b Productivity measures are derived from the WPAI.
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(all p b 0.003). Differences in health utility (N0.041) scores exceededTable 3
Relationship between seizure frequency and patient characteristics for covariate selection.
US p-values for Seizure
Frequency Association
Age (years) —mean ± SD 0.003
Female (%) 0.098
Race/ethnicity b .001
Married/living with partner (%) 0.378
College educated (%) 0.003
Annual household income b .001
Employed (%) b .001
Retired (%) 0.654
Long-term disability (%) b .001
Insured (%) 0.055
Body mass index 0.021
Consume alcohol (%) 0.061
Smoking behavior b .001
Exercise (%) 0.841
Charlson comorbidity index —mean ± SD b .001
Length of time diagnosed with epilepsy b .001
Total number of epilepsy prescriptions b .001MIDs for patients that reported ≥1 seizures a week or 1–3 seizures per
month, relative to patients that reported b1 seizure per year.5EU p-values for Seizure
Frequency Association
Brazil + 5EU p-values for
Seizure Frequency Association
0.008 0.021
0.350 0.408
N/A N/A
0.137 0.314
0.990 0.951
0.005 0.003
0.019 0.032
0.034 0.029
0.153 0.128
N/A N/A
0.113 0.173
0.362 0.129
0.005 0.014
0.651 0.524
0.006 0.061
0.294 0.377
b .001 b .001
Table 4
Unadjusted outcomes values by seizure frequency group.
Total ≥1 times a
week
1–3 times a
month
1–4 times a
year
b1 time a
year
p-Value for
relationship
to seizure
frequency
US
Sample size 782 85 100 172 425
MCS —mean ± SD 44.60 ± 12.31 37.62 ± 13.59 39.13 ± 11.93 43.95 ± 12.38 47.56 ± 11.04 b .001
PCS —mean ± SD 46.44 ± 10.93 41.69 ± 11.40 42.30 ± 10.32 45.53 ± 11.31 48.72 ± 10.20 b .001
Health utility —mean ± SD 0.68 ± 0.15 0.60 ± 0.15 0.61 ± 0.12 0.66 ± 0.14 0.72 ± 0.14 b .001
Absenteeisma,b (%) —mean ± SD 6.78 ± 17.43 30.18 ± 34.64 6.38 ± 12.31 9.07 ± 19.31 3.91 ± 12.58 b .001
Presenteeisma,b (%) —mean ± SD 23.05 ± 28.16 47.73 ± 35.98 41.92 ± 30.86 29.50 ± 28.31 16.68 ± 24.12 b .001
Overall work impairmenta,b (%) —mean ± SD 26.17 ± 30.79 57.32 ± 38.76 44.00 ± 32.38 33.75 ± 30.64 18.97 ± 26.44 b .001
Activity impairmentb (%) —mean ± SD 33.67 ± 31.90 52.71 ± 32.64 47.50 ± 32.86 36.51 ± 29.81 25.46 ± 29.41 b .001
Healthcare provider visits in past 6 months (mean ± SD) 6.36 ± 9.20 10.46 ± 11.89 10.17 ± 13.64 4.99 ± 5.91 5.21 ± 7.83 b .001
ER visits in the past 6 months (mean ± SD) 0.71 ± 2.41 1.92 ± 4.10 0.97 ± 2.41 0.92 ± 3.25 0.31 ± 1.11 b .001
Hospitalizations in the past 6 months (mean ± SD) 0.25 ± 0.89 0.85 ± 1.81 0.27 ± 0.74 0.35 ± 1.03 0.09 ± 0.41 b .001
5EU
Sample size 418 43 44 84 247
MCS —mean ± SD 43.21 ± 11.75 37.84 ± 10.84 41.47 ± 8.89 39.28 ± 10.17 45.79 ± 12.16 b .001
PCS —mean ± SD 46.20 ± 10.55 39.74 ± 11.85 42.88 ± 9.07 44.75 ± 10.33 48.41 ± 9.97 b .001
Health utility —mean ± SD 0.67 ± 0.14 0.58 ± 0.13 0.63 ± 0.10 0.62 ± 0.12 0.71 ± 0.14 b .001
Absenteeisma,b (%) —mean ± SD 9.30 ± 22.13 15.65 ± 25.25 16.12 ± 22.45 15.12 ± 26.61 6.09 ± 19.73 0.024
Presenteeisma,b (%) —mean ± SD 23.71 ± 28.49 48.42 ± 36.40 37.65 ± 27.73 31.71 ± 30.98 16.67 ± 23.65 b .001
Overall work impairmenta,b (%) —mean ± SD 28.72 ± 32.56 52.80 ± 38.30 46.47 ± 31.25 37.64 ± 34.65 21.11 ± 28.42 b .001
Activity impairmentb (%) —mean ± SD) 36.51 ± 31.97 60.47 ± 29.35 48.86 ± 26.08 43.81 ± 31.04 27.65 ± 30.29 b .001
Healthcare provider visits in past 6 months (—mean ± SD) 7.15 ± 9.56 9.70 ± 13.57 7.36 ± 9.30 9.89 ± 12.28 5.73 ± 7.19 0.001
ER visits in the past 6 months (—mean ± SD) 0.51 ± 1.39 1.37 ± 3.07 0.84 ± 1.33 0.69 ± 1.22 0.25 ± 0.78 b .001
Hospitalizations in the past 6 months (—mean ± SD) 0.37 ± 1.14 1.07 ± 2.42 0.61 ± 1.24 0.65 ± 1.34 0.11 ± 0.37 b .001
Brazil+ 5EU
Sample size 452 47 45 92 268
MCS —mean ± SD 43.13 ± 12.09 37.27 ± 11.57 41.53 ± 8.80 39.80 ± 10.98 45.57 ± 12.40 b .001
PCS —mean ± SD 46.41 ± 10.48 41.08 ± 12.23 42.80 ± 8.99 45.14 ± 10.51 48.39 ± 9.86 b .001
Health utility —mean ± SD 0.67 ± 0.14 0.58 ± 0.14 0.63 ± 0.10 0.62 ± 0.12 0.71 ± 0.14 b .001
Absenteeisma,b (%) —mean ± SD 10.26 ± 23.44 14.23 ± 24.46 15.50 ± 21.94 16.07 ± 28.58 7.51 ± 21.54 0.085
Presenteeisma,b (%) —mean ± SD 24.42 ± 28.88 43.81 ± 37.48 38.89 ± 27.42 30.91 ± 30.33 18.34 ± 25.26 b .001
Overall work impairmenta,b (%) —mean ± SD 29.97 ± 33.20 48.00 ± 39.61 47.33 ± 30.53 37.91 ± 34.88 23.37 ± 30.15 b .001
Activity impairmentb (%) —mean ± SD 36.53 ± 32.26 56.81 ± 30.86 49.11 ± 25.83 43.70 ± 31.61 28.40 ± 30.98 b .001
Healthcare provider visits in past 6 months (—mean ± SD) 7.17 ± 9.57 9.79 ± 13.11 7.33 ± 9.20 9.49 ± 11.91 5.88 ± 7.62 0.003
ER visits in the past 6 months (—mean ± SD) 0.53 ± 1.39 1.30 ± 2.96 0.84 ± 1.31 0.71 ± 1.26 0.28 ± 0.87 b .001
Hospitalizations in the past 6 months (—mean ± SD) 0.37 ± 1.12 1.00 ± 2.33 0.60 ± 1.23 0.63 ± 1.29 0.13 ± 0.47 b .001
Note:Overall p-values are provided indicating at least one group is different from another. Lower scores onMental Component Summary (MCS), Physical Component Summary (PCS), and
health utilities indicate a decrease in quality of life. Absenteeism, presenteeism, overall work impairment and activity impairment scores represent impairment percentages, with higher
scores indicating greater impairment. ER = emergency room, IGE = idiopathic generalized epilepsy, SD = standard deviation.
a Includes only employed respondents.
b Productivity measures are derived from the WPAI.
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had less overall work and activity impairment than respondents
that reported having seizures more often (all p b 0.02). Respon-
dents that experienced b1 seizure a year had fewer provider visits
than respondents that reported ≥1 seizures per week (p b 0.001)
or 1–3 seizures a month (p = 0.004). For the more frequent
seizure groups, the number of ER visits was signiﬁcantly great-
er than those for the b1 seizure per year group (all p b 0.04).
Hospitalizations in the past six months also increased with more
frequent seizures (b1 seizure/year vs. ≥1 seizures/week, p b 0.001)
(Table 5).
After adjustments, seizure frequency was positively related to
indirect costs. Speciﬁcally, as seizures occurred more often, pa-
tients' indirect costs also increased. Assuming 100% missed
work for the unemployed, working age respondents (aged 18–
60 years), those with more frequent seizures had signiﬁcantly
higher indirect costs than patients reporting less than one seizure
per year (all p b 0.001). The more frequent seizure groups addition-
ally incurred signiﬁcantly higher direct costs than participants who
reported experiencing less than one seizure a year (all p b 0.02)
(Table 5).3.2.2.2. 5EU IGE. Differences in MCS and PCS (N3) QoL scores exceeded
MIDs for patients that reported 1–3 seizures a month and ≥1 seizures
per week, compared with patients that reported b1 seizure per year
(all p b 0.05). Patients that reported having less than one seizure per
year had higher SF-6D health utility scores than the threemore frequent
seizure groups (all p b 0.001).
Patients that reported having less than one seizure per year
had less overall work impairment (all p b 0.05) and activity impair-
ment (all p b 0.001) than respondents that reported having seizures
more often, after controlling for covariates. The number of provider
visits was signiﬁcantly greater for the 1–4 seizures per year group
than for the b1 seizure a year group (p = 0.003). The number of
ER visits was signiﬁcantly higher for the more frequent seizure
groups than for the b1 seizure per year group (all p b 0.001). Fur-
thermore, patients in the three frequent seizure groups had signiﬁ-
cantly more hospitalizations in the past six months than patients
who experienced seizures less than once per year (all p b 0.001)
(Table 5).
After adjustments, both direct and indirect costs increased, as sei-
zure frequency increased. Assuming 100% missed work for the unem-
ployed respondents, who were of an employable age (18–60 years),
Table 5
Adjusted outcomes values and pairwise comparisons to lowest seizure frequency group.
Parameter ≥1 seizures/week 1–3 seizures/month 1–4 seizures/year b1 seizure/year
US outcomes values
Sample size 85 100 172 425
MCS LSMeans 39.18 40.48 45.05 46.48
p-Value b .0001 b .0001 0.1787
PCS LSMeans 43.10 43.77 46.02 47.90
p-Value b .0001 0.0002 0.0382
Health utilities LSMeans 0.619 0.628 0.673 0.711
p-Value b .0001 b .0001 0.0024
Absenteeism%a,b LSMeans 21.04 4.86 8.22 3.98
p-Value 0.0444 0.7732 0.1231
Presenteeism%a,b LSMeans 39.23 37.62 26.88 17.05
p-Value 0.0129 0.0055 0.0261
Overall work impairment%a,b LSMeans 48.14 39.72 30.71 19.39
p-Value 0.0051 0.0087 0.0184
Activity impairment%b LSMeans 45.45 40.28 32.49 25.51
p-Value b .0001 0.0001 0.013
Provider visits LSMeans 8.52 7.53 4.95 4.88
p-Value 0.0005 0.0041 0.9107
ER visits LSMeans 1.30 0.52 0.69 0.28
p-Value b .0001 0.0361 0.0002
Hospitalizations LSMeans 0.49 0.15 0.27 0.09
p-Value b .0001 0.1998 0.0004
Absenteeism costs ($)a,b LSMeans 6592.64 1308.90 4544.76 1665.38
p-Value 0.1257 0.7540 0.0616
Presenteeism costs ($)a,b LSMeans 9818.06 11,288 8327.59 5317.66
p-Value 0.0710 0.0138 0.0431
Total indirect costs ($)a,b LSMeans 17,072 12,799 12,323 7114.65
p-Value 0.0154 0.0592 0.0157
Total indirect costs (age 18–60) ($)a,b LSMeans 32,751 29,758 28,594 19,184
p-Value b .0001 b .0001 b .0001
Provider visit costs ($) LSMeans 20,479 17,290 12,021 11,473
p-Value 0.0007 0.0110 0.7272
ER visit costs ($) LSMeans 3844.83 1388.44 2227.64 775.91
p-Value b .0001 0.0944 0.0002
Hospitalization costs ($) LSMeans 18,489 5004.86 8531.14 2475.20
p-Value 0.0003 0.1638 0.0024
Total direct costs ($) LSMeans 43,086 24,309 24,518 15,978
p-Value b .0001 0.0185 0.0041
5EU outcomes values
Sample size 43 44 84 247
MCS LSMeans 38.99 41.61 40.11 45.28
p-Value 0.0008 0.0441 0.0003
PCS LSMeans 40.08 43.69 45.27 48.03
p-Value b .0001 0.0041 0.0195
Health utilities LSMeans 0.589 0.634 0.627 0.707
p-Value b .0001 0.0004 b .0001
Absenteeism%a,b LSMeans 17.74 18.59 15.96 5.18
p-Value 0.1134 0.104 0.0418
Presenteeism%a,b LSMeans 49.30 39.79 30.34 15.91
p-Value 0.0009 0.0074 0.0088
Overall work impairment%a,b LSMeans 51.21 47.39 36.23 20.87
p-Value 0.0033 0.0105 0.0141
Activity impairment%b LSMeans 55.87 46.89 40.52 26.65
p-Value b .0001 0.0005 0.0008
Provider visits LSMeans 8.40 6.74 9.52 5.77
p-Value 0.0889 0.465 0.0027
ER visits LSMeans 0.93 0.77 0.61 0.22
p-Value b .0001 0.0006 0.0008
Hospitalizations LSMeans 0.58 0.56 0.52 0.11
p-Value b .0001 b .0001 b .0001
Absenteeism costs (€)a,b LSMeans 2027.02 2069.08 2569.75 1244.03
p-Value 0.5873 0.5492 0.2126
Presenteeism costs (€)a,b LSMeans 5187.53 5735.75 4595.81 2543.76
p-Value 0.0624 0.0390 0.0380
Total Indirect costs (€)a,b LSMeans 6524.98 7659.03 6883.54 3847.49
p-Value 0.1421 0.0705 0.0297
Total indirect costs (age 18–60) (€)a,b LSMeans 13,671 14,041 12,386 8264.54
p-Value 0.0014 0.0016 0.0011
Provider visit costs (€) LSMeans 563 439.31 641.27 368.97
p-Value 0.0777 0.4425 0.0024
ER visit costs (€) LSMeans 259.36 208.66 156.55 47.28
p-Value 0.0012 0.0027 0.0022
Hospitalization costs (€) LSMeans 1258.74 1503.40 1228.28 234.13
p-Value 0.0068 0.0011 0.0003
5EU outcomes values
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Table 5 (continued)
Parameter ≥1 seizures/week 1–3 seizures/month 1–4 seizures/year b1 seizure/year
Total direct costs (€) LSMeans 2233.52 2051.92 1922.06 708.21
p-Value 0.0001 0.0001 b .0001
Brazil+ 5EU outcomes values
Sample size 47 45 92 268
MCS LSMeans 38.23 41.33 40.35 45.25
p-Value 0.0001 0.0357 0.0005
PCS LSMeans 41.28 43.55 45.61 48.07
p-Value b .0001 0.0027 0.0301
Health utilities LSMeans 0.593 0.630 0.631 0.706
p-Value b .0001 0.0003 b .0001
Absenteeism%a,b LSMeans 13.23 16.10 16.24 7.10
p-Value 0.3384 0.2286 0.0726
Presenteeism%a,b LSMeans 44.58 41.37 29.80 17.20
p-Value 0.0024 0.0068 0.0162
Overall work impairment%a,b LSMeans 47.19 48.44 37.02 22.84
p-Value 0.0107 0.0132 0.0198
Activity impairment%b LSMeans 52.73 47.85 41.08 27.54
p-Value b .0001 0.0005 0.0009
Provider visits LSMeans 8.73 6.74 9.31 5.86
p-Value 0.0613 0.5102 0.0040
ER visits LSMeans 0.91 0.79 0.66 0.25
p-Value 0.0001 0.0011 0.0006
Hospitalizations LSMeans 0.55 0.56 0.53 0.13
p-Value 0.0001 b .0001 b .0001
Note: Pairwise p-values are provided indicating one group is different than another. Lower scores onMental Component Summary (MCS), Physical Component Summary (PCS) and health
utilities indicate a decrease in quality of life. Absenteeism, presenteeism, overall work impairment and activity impairment scores represent impairment percentages, with higher scores
indicating greater impairment. ER = emergency room, IGE = idiopathic generalized epilepsy, SD = standard deviation.
a Includes only employed respondents.
b Productivity measures are derived from the WPAI.
Table 6
The prevalence estimates in the US, 5EU, and Brazil.
Country Epilepsy overall (per 1000)
United States 7.1 (Hirtz et al.) [17]
France 5.4 (Picot et al.) [18]
Germany 9.1 (Hamer et al.) [19]
Italy 4.57 (Giussani et al.) [20]
Spain 4.79 (Garcia-Martin et al.) [21]
United Kingdom 8.6 (Ferro) [22]
Brazil 10.7 (Bruno et al.) [23]
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costs than the b1 seizure a year group (all p b 0.01). Total direct costs
were also greater for the three more frequent seizure groups than for
the b1 seizure a year group (all p b 0.001) (Table 5).
3.2.2.3. Brazil + 5EU IGE. Patients that reported having less than one
seizure per year had better MCS, PCS, and health utility scores, com-
paredwith the other three seizure groups (all p b 0.05), after control-
ling for covariates. Differences in MCS and PCS QoL scores exceeded
MIDs (N3) for patients that reported 1–3 seizures a month or ≥1 sei-
zures per week, relative to patients that reported b1 seizure per year.
Patients that reported 1–4 seizures a year also exceeded the MID on
MCS, compared with patients reporting ≥1 seizures per week. Differ-
ences in health utility scores exceeded MIDs (N0.041) for patients
that reported ≥1 seizures per week, 1–3 seizures per month, and 1–
4 seizures a year, compared with patients that reported b1 seizure
per year.
After adjustments, among the employed respondents, there were
no signiﬁcant differences between seizure groups on absenteeism.
However, patients that experienced b1 seizure per year reported
less presenteeism and overall work impairment than the three
more frequent seizure groups (all p b 0.05). Patients that experi-
enced ≥1 seizures per week reported over 100% more overall
work impairment than the b1 seizure per year group (p = 0.011).
Among all respondents, as the number of seizures decreased, activity
impairment also decreased. Patients that experienced ≥1 seizures a
week reported 92% more activity impairment than the b1 seizure a
year group (p b 0.001).
After controlling for covariates, patients that reported 1–4 seizures
per year had signiﬁcantly more traditional provider visits in the past
six months than patients that reported b1 seizure per year (59%, p =
0.004). As the number of seizures decreased, the number of ER visits
and the number of hospitalizations in the past six months also de-
creased. Patients that had ≥1 seizures per week reported signiﬁcantly
more ER visits (261%, p b 0.001) and hospitalizations (336%, p b 0.001)than patients that reported less than one seizure per year. Patients
that reported 1–3 seizures a month also reported signiﬁcantly more ER
visits (215%, p = 0.001) and hospitalizations (345%, p b 0.001) than pa-
tients that reported b1 seizure per year. Patients that had 1–4 seizures
per year also reported signiﬁcantly more ER visits (163%, p b 0.001)
and hospitalizations (324%, p b 0.001) than patients that reported less
than one seizure per year (Table 5).4. Discussion
Over 50 million people worldwide currently have epilepsy, with
over two million new cases of epilepsy diagnosed each year [16]. Epi-
lepsy prevalence varies considerably by region (Table 6). Therefore, it
is important to understand the patient burden of this condition by epi-
lepsy type, and hence, the overall objective of this current study was to
extend and update the literature with respect to the burden of PGTCS
and IGE/GGE, among patients diagnosed with epilepsy in the US, 5EU
(France, Germany, Italy, Spain, and UK), and Brazil. Overall, the results
suggested a signiﬁcant burden existed across all three regions for pa-
tients with IGE with insufﬁciently managed seizures. In the current
study, nearly half of participants from each region reported experienc-
ing seizures once per year ormore often. Theseﬁndingswere consistent
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number of patients with uncontrolled disease, despite receiving one or
more AEDs. Speciﬁcally, prior research for the overall epilepsy popula-
tion reports that over half of patients who used monotherapy [16] and
nearly three quarters of adult patients with focal epilepsy who were
treated with two or more AEDs [24,25] were still unable to achieve dis-
ease control.
Across the US and 5EU, similar distributions of age and gender
were observed. The Brazilian sample was slightly younger and more
likely to be female than the US and 5EU samples. Between 51% and
58% of respondents were married/living with a partner, 30% to 35% of
respondentswere college educated, and on average, CCI scoreswere be-
tween 0.6 and 1.2 across all three regions. The patterns of QoL, health
utilities, productivity loss, activity impairment, and resource utilization
in Brazil and the 5EUwere not statistically different. Hence, similar bur-
den was observed in Brazil and the 5EU. Overall, the patient burden of
IGE increased as seizure frequency increased in both the US and 5EU.
Seizure frequency matters for QoL. Patients with one or more sei-
zures per week demonstrated statistically signiﬁcant and meaningful
decrements in mental and physical health and in health status (utility),
comparedwith patients with less than one seizure per year. Themajor-
ity of results also exceeded MIDs. These ﬁndings were consistent with
research for the overall epilepsy population showing that seizure fre-
quencywas negatively related to patient QoL in adults [26] and opposed
overall epilepsy population research that has indicated no association of
seizure frequency with QoL [27]. Some QoL studies may have difﬁculty
showing a relationship between QoL and seizure frequency as AEDs
may improve QoL by providing improved seizure control while simulta-
neouslyworseningQoL through the potential addition of adverse events
[28]. A prior study among adults treated with AEDs reported that de-
creased QoLwas associatedwith continued seizures and adverse events
(ages 5 years and older, 12.3% IGE) [29]. Additionally, a QoL study in
Korean patients with epilepsy (ages 20–70 years) of which 19.5% had
a generalized epilepsy syndrome demonstrated an independent asso-
ciation between seizure control (deﬁned as: well-controlled, poorly
controlled, uncontrolled) and QoL (measured by the QOLIE-10 domain:
role functioning and mental health) [30]. The relationship between sei-
zure frequency and other outcomes such as healthcare resource utiliza-
tion and productivity may also be similarly impacted.
Among patients with IGE, ER visits and hospitalizations signiﬁcantly
increased, as the number of seizures increased (in many cases, these
increases were over 100%). These ﬁndings were in line with adult
focal epilepsy research suggesting that patients with uncontrolled epi-
lepsy have higher healthcare resource utilization [24]. Particularly,
these adult patients with uncontrolled epilepsy may make more fre-
quent visits to ERs and have longer hospital LOS [31]. Furthermore,
they may receive a larger number of medications and undergo medical
testing more often [25]. Generally, healthcare provider visits also differ
between the frequency seizure groups. These ﬁndings were similar to
previous published literature. Speciﬁcally, prior research for the overall
adult epilepsy population has found that patients with unmanaged dis-
ease have signiﬁcantly more healthcare provider visits than those with
effectively controlled seizures [31]. Although the annual costs for AEDs
were not collected in the current study, prior research suggests that
one of the biggest components of overall direct costs is AED-related
costs (children and adults, 8.2% IGE) [32].
Overall work and activity impairment scores monotonically in-
creased with increasing seizure frequency. It is important to note that
the number of employed patients was relatively small, but their average
age was, at less than 50 years, below the traditional retirement age. Pa-
tients with frequent seizures weremore likely to be on disability or may
have decided to retire, as a result of their disease. This ﬁndingmay have
considerable implications for indirect costs, as research for the overall
epilepsy population has demonstrated that epilepsy-related absentee-
ism accounted for more than three-quarters of annual indirect per
patient costs [33]. Additionally, reduced employment participation,due to epilepsy overall, can potentially result in thousands of euros
(or dollars) in lost wages each year [34]. Particularly, over two-thirds
of indirect epilepsy costs have been found to be due to early retirement
or days taken off fromwork for seizures, and indirect costs accounted for
almost 70% of the total annual per patient epilepsy-related costs [35].
Similarly, another study found that indirect costs were higher than di-
rect costs in adults with active epilepsy (19.8% patients with IGE) [36].
Indirect (assuming employable age) and direct costs were signiﬁ-
cantly higher for patients that experienced more frequent seizures.
Likewise, prior research for the overall epilepsy population shows that
adult patients with inadequately managed disease have collective year-
ly costs that are almost double those incurred by patients that have
achieved seizure control [31]. Direct costs among patients with drug-
resistant epilepsyweremore than twice those found for seizure-free pa-
tients [25].
The current study made a number of contributions to the literature.
Speciﬁcally, few studies have investigated QoL among patients with
IGE/GGE [3,37] alone, and even fewer recent studies have done so as a
function of IGE/GGE seizure frequency [30]. Thus, ﬁndings increased
the understanding of a broader array of QoL outcomes and how
these outcomes may differ by the number of seizures experienced. Fur-
thermore, by examining the indirect and direct costs associated with
seizure frequency, the results provided amore comprehensive portrayal
of the economic burden associated with IGE.
Our ﬁndings have meaningful implications for the ﬁnancial burden
of epilepsy on healthcare systems. For instance, research using claims
data shows that annual costs associated with epilepsy were over three
and a half times higher than costs estimated for matched controls [38].
Other data have demonstrated that epilepsy-related costs can account
for anywhere from 0.2 to 1% of total national direct and/or indirect
healthcare expenses [19,33]. Adequate disease management among pa-
tients will be important for curbing these costs at the national level. De-
spite the availability of existing AEDs in 2013, the results suggested that
patients with IGE in the US, 5EU, and Brazil are in need of additional
treatment options, for which newer AED may provide a solution.
A major advantage of this study was the ability to evaluate the
effects of seizure frequency on different types of burden within one
study, using a large, representative database. While claims data are a
useful source of information for resource utilization and costs, they do
not report seizure frequency or health utility values. Clinical cohort
studies are helpful for determining seizure frequency and QoL, but
they often do not report information on costs attributed to resource uti-
lization or productivity loss. Additionally, past studies have emphasized
the major dichotomy in many patient-related outcomes between being
completely seizure-free and having occasional seizures or auras [39],
but our results suggested that even lesser degrees of seizure reduction
can have major impacts on QoL and economic outcomes.
4.1. Limitations
Some factors may limit the external validity of our ﬁndings. Self-
reported data were collected to assess the relationships among the
study variables without veriﬁcation of diagnoses, treatment, or seizure
frequency. As such, we cannot rule out the possibility that the metrics
reported by respondentswere inﬂuenced, at least to some extent, by re-
call biases. Additionally, it is possible that some patients misclassiﬁed
their seizure type (e.g., complex partial seizures may be confused with
absences, secondarily generalized tonic–clonic seizures with PGTCS).
Patients were given the option to respond as “Don't know”, allowing
them an option if they were not sure about their seizure type diagnosis.
Nevertheless, the study IGE prevalence value of 4 per 1000 is fairly large
compared with the overall epilepsy prevalence (Table 6). A French
study estimated IGE to be 1.8 per 1000 [18] and a Spanish study estimat-
ed IGE to be 16% of all patients with epilepsy [40]. Given the high likeli-
hood of other seizure types in this analysis and the fact that PGTCS tends
to be more severe and less frequent than other seizure types, it is likely
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larger impact on QoL, productivity, and healthcare resource utilization
at lower seizure frequency levels. The inclusion of other seizure types
may also explain the high prevalence of carbamazepine and phenytoin
use reported in this population (Table 1). Because of the internet-
based study design, resultsmay not be generalizable to all adult patients
with IGE. Speciﬁcally, some adults in the US, 5EU, and Brazil with IGE
may not have had access to a computer or may have been limited in
their experience with such technology. Only adult patients mentally
and physically capable of completing the questionnaire were included.
Additionally, there may also be some selection bias of the respon-
dents included in the study. Those more severely affected by their epi-
lepsy seizures may possibly be more inclined to report their epilepsy,
or those who are seizure-free may no longer consider themselves as
having epilepsy. This study of a prevalent adult cohort with IGE reports
that over 40% of patients reported having persistent seizures (1 ormore
per year in the past year) while other reports of newly diagnosed pa-
tients estimate this to be 33% of patients with IGE (ages 9–93 years)
[41], and 44% for the ﬁrst AED and approximately 50% for the second
AED among those who had seizures that failed to improve with their
ﬁrst AED (ages 5 years and older, 19% generalized-onset) [42]. Addition-
ally, the questionnaire did not collect information speciﬁcally onwheth-
er patientswere considered seizure-free by their physicians or how long
they have been seizure-free.
Because the data were cross-sectional in nature, causal inferences
cannot be made regarding the relationships of interest. Furthermore,
some of the ﬁndings must be evaluated with caution, due to the low
sample sizes used to perform a subset of the analyses. Adjustments for
multiple pairwise comparisons were not performed. It is possible that
some of the signiﬁcant differences reported were due to chance. There
were very few p-values between 0.05 and 0.0167 (Bonferroni thresh-
old). A majority of these were in the comparison between 1 and 4 sei-
zures per year and b1 seizure per year. Future research will be needed
to verify these comparisons.
4.2. Conclusions
The core strength of this study was that it utilized patient-reported
outcomes to determine seizure frequency, QoL, productivity, and HRU.
Assessment from the patient's perspective is vital, especially for exam-
iningmore subjective outcomes, such as QoL and productivity. A greater
burden was consistently associated with an increased frequency of sei-
zures. Given the number of patients reporting more than 1 seizure a
year and the substantial differences between this and lower seizure fre-
quencies (1–4 per year, 1–3 per month) on many outcomes, there is
clearly a need for additional treatment options among patients with
PGTCS and IGE/GGE to increase the number of individual patients
reaching seizure freedom. Additional options for disease management
may not only improve QoL for affected patients butmay likewise reduce
the direct and indirect costs resulting from inadequate seizure control.
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